Swiss National Bank Purchases 1,000 Shares of Zimmer Biomet Holdings Inc (ZBH)

Swiss National Bank lifted its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 0.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 744,416 shares of the medical equipment provider’s stock after purchasing an additional 1,000 shares during the quarter. Swiss National Bank’s holdings in Zimmer Biomet were worth $89,829,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ZBH. Longview Partners Guernsey LTD boosted its position in shares of Zimmer Biomet by 17.7% during the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after buying an additional 1,128,973 shares during the period. Alyeska Investment Group L.P. boosted its position in shares of Zimmer Biomet by 249.3% during the third quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock worth $119,417,000 after buying an additional 727,925 shares during the period. Jana Partners LLC boosted its position in shares of Zimmer Biomet by 16.6% during the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after buying an additional 662,497 shares during the period. American Century Companies Inc. boosted its position in shares of Zimmer Biomet by 14.7% during the fourth quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock worth $576,488,000 after buying an additional 612,044 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Zimmer Biomet by 24.4% during the third quarter. Bank of New York Mellon Corp now owns 2,759,704 shares of the medical equipment provider’s stock worth $323,134,000 after buying an additional 541,102 shares during the period. 86.36% of the stock is owned by institutional investors.

Zimmer Biomet Holdings Inc (NYSE ZBH) opened at $116.52 on Tuesday. Zimmer Biomet Holdings Inc has a 52-week low of $108.03 and a 52-week high of $133.49. The company has a current ratio of 1.52, a quick ratio of 0.83 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $23,565.84, a P/E ratio of 12.93, a P/E/G ratio of 2.04 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, meeting the consensus estimate of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The firm had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period in the prior year, the firm posted $2.14 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. equities analysts predict that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were paid a $0.24 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.82%. Zimmer Biomet’s dividend payout ratio is 10.65%.

Several research firms have recently weighed in on ZBH. Cantor Fitzgerald reaffirmed a “buy” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Monday, February 5th. BMO Capital Markets reaffirmed a “buy” rating and set a $144.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, January 30th. Leerink Swann upped their price objective on Zimmer Biomet from $142.00 to $146.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Stifel Nicolaus raised Zimmer Biomet from a “hold” rating to a “buy” rating and upped their price objective for the stock from $120.00 to $168.00 in a research report on Wednesday, January 31st. Finally, Robert W. Baird reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $141.67.

ILLEGAL ACTIVITY WARNING: This article was reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.com-unik.info/2018/02/13/swiss-national-bank-purchases-1000-shares-of-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit